Forty Seven, Inc.
CIK 0001667633AcceleratedSmaller ReportingEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2019
Revenue
$15.68M
Net Income
$-87.62M
Total Assets
$343.59M
Equity
$317.93M
Shares Out
48.16M
Op. Cash Flow
$-78.11M
Business
Forty Seven, Inc. is a former operating company in Pharmaceutical Preparations, incorporated in Delaware. Securities are no longer actively traded on a major U.S. exchange.
Auto-generated from company profile
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2019 2019-12-31 | FY 2018 2018-12-31 | FY 2017 2017-12-31 | FY 2016 2016-12-31 |
|---|---|---|---|---|---|
| License revenue | 16 | — | — | — | |
| Research and development | 84 | 57 | 37 | 14 | |
| General and administrative | 20 | 15 | 8 | 5 | |
| Total operating expenses | 104 | 72 | 45 | 20 | |
| Loss from operations | −89 | −72 | −45 | −20 | |
| Remeasurement loss on contingent repayment obligation | −3 | −331,000 | — | — | |
| Interest and other income, net | 3 | 2 | 406,000 | 78,000 | |
| Net loss | −88 | −70 | −45 | −20 | |
| Unrealized gains (losses) on available-for-sale securities | 174,000 | −38,000 | −44,000 | — | |
| Comprehensive loss | −87 | −70 | −45 | −20 | |
| Net loss per share, basic and diluted | −2.4 | −3.75 | −6.94 | −3.15 | |
| Shares used in computing net loss per share, basic and diluted | 36 | 19 | 6 | 6 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2019 2019-12-31 | FY 2018 2018-12-31 | FY 2017 2017-12-31 | FY 2016 2016-12-31 | FY 2015 2015-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 214 | 11 | 24 | — | — | |
| Short-term investments | 115 | 128 | 64 | — | — | |
| Prepaid expenses and other current assets | 8 | 7 | 4 | — | — | |
| Total current assets | 338 | 146 | 93 | — | — | |
| Property and equipment, net | 1 | 1 | 1 | — | — | |
| Operating lease right-of-use assets | 2 | — | — | — | — | |
| Other assets | 3 | 2 | 2 | — | — | |
| Total assets | 344 | 149 | 95 | — | — | |
| Accounts payable | 9 | 5 | 4 | — | — | |
| Accrued liabilities | 9 | 9 | 5 | — | — | |
| Lease liabilities, current | 1 | — | — | — | — | |
| Deferred grant funding, current | 3 | 2 | 3 | — | — | |
| Other current liabilities | 859,000 | — | — | — | — | |
| Total current liabilities | 23 | 15 | 11 | — | — | |
| Lease liabilities, noncurrent | 844,000 | — | — | — | — | |
| Deferred rent, noncurrent | — | 331,000 | — | — | — | |
| Other long-term liabilities | 2 | 476,000 | 255,000 | — | — | |
| Total liabilities | 26 | 16 | 12 | — | — | |
| Commitments and Contingencies (Note 6) | — | — | — | — | — | |
| Common stock, $0.0001 par value: 200,000,000 shares authorized; 47,983,366 and 31,079,150 shares issued and outstanding at December 31, 2019 and 2018, respectively | 5,000 | 3,000 | 1,000 | — | — | |
| Additional paid-in capital | 545 | 273 | 4 | — | — | |
| Accumulated other comprehensive gain (loss) | 92,000 | −82,000 | −44,000 | — | — | |
| Accumulated deficit | −227 | −140 | −69 | — | — | |
| Total stockholders equity | 318 | 133 | 83 | 12 | 27 | |
| Total liabilities and stockholders equity | 344 | 149 | 95 | — | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2019 2019-12-31 | FY 2018 2018-12-31 | FY 2017 2017-12-31 | FY 2016 2016-12-31 |
|---|---|---|---|---|---|
| Net loss | −88 | −70 | −45 | −20 | |
| Stock-based compensation | 5 | 3 | 724,000 | 245,000 | |
| Depreciation and amortization | 523,000 | 401,000 | 371,000 | 134,000 | |
| Amortization of right-of-use assets | 1 | 0 | — | — | |
| Accretion of discounts on marketable securities | −1 | −744,000 | 0 | 0 | |
| Realized gain on sale of available-for-sale securities | −6,000 | 0 | — | — | |
| Change in fair value of contingent repayment obligation | 3 | 331,000 | 0 | 0 | |
| Prepaid expenses and other current assets | −2 | −2 | −568,000 | −4 | |
| Other assets | −651,000 | −673,000 | 205,000 | −2 | |
| Accounts payable | 4 | 916,000 | 1 | 2 | |
| Accrued liabilities | −107,000 | 4 | 3 | 853,000 | |
| Deferred grant funding | 1 | −1 | 3 | 0 | |
| Lease related liabilities | −1 | −123,000 | −90,000 | 53,000 | |
| Net cash used in operating activities | −78 | −66 | −37 | −22 | |
| Purchases of property and equipment | −356,000 | −403,000 | −114,000 | −1 | |
| Purchases of available-for-sale securities | −166 | −142 | −80 | −4 | |
| Proceeds from sales of available-for-sale securities | 4 | 0 | — | — | |
| Proceeds from maturities of available-for-sale securities | 176 | 78 | 16 | 4 | |
| Net cash provided by (used in) investing activities | 14 | −64 | −64 | −1 | |
| Proceeds from issuance of common stock upon ESPP purchase | 859,000 | 0 | — | — | |
| Proceeds from issuance of common stock upon exercise of stock options | 2 | 291,000 | 312,000 | 436,000 | |
| Proceeds from public offerings of common stock, net of issuance costs | 264 | 116 | — | — | |
| Repurchase of fractional common stock upon reverse stock split | 0 | −1,000 | 0 | 0 | |
| Net cash provided by financing activities | 267 | 117 | 115 | 5 | |
| Net increase (decrease) in cash and cash equivalents | 203 | −14 | 15 | −18 | |
| Operating cash flows paid for operating leases | 1 | 0 | — | — | |
| Lease liability obtained in exchange for right-of-use asset | 712,000 | 0 | — | — | |
| Public offering costs included in accrued liabilities | 264,000 | 0 | — | — | |
| Property and equipment purchases included in accrued liabilities | 30,000 | — | — | — | |
| Conversion of convertible preferred stock to common stock at close of initial public offering | 0 | 149 | 0 | 0 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is Forty Seven, Inc.'s CIK number?
Forty Seven, Inc.'s SEC CIK number is 0001667633 (1667633). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Forty Seven, Inc.'s SEC filings?
All of Forty Seven, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.